| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
2MeSATP targets P2X and P2Y purinergic receptors. It acts as a potent agonist at P2X1, P2X3, and P2X7 receptors, as well as P2Y1 and P2Y11 receptors. The methylthio substitution at the 2-position enhances receptor potency and stability compared to ATP. P2X receptors are ligand-gated ion channels, while P2Y receptors are G-protein coupled receptors. Activation of these receptors mediates various physiological processes including neurotransmission, platelet aggregation, inflammation, and pain signaling.
|
|---|---|
| ln Vitro |
In vitro, 2MeSATP acts as a potent P2X and P2Y receptor agonist. It is more potent than ATP at many P2 receptors and is resistant to degradation by ectonucleotidases. The compound induces calcium mobilization in cells expressing P2Y receptors and evokes inward currents in cells expressing P2X receptors. No specific EC50 values are provided in the available literature. It is used as a research tool for studying purinergic signaling in various cell types including neurons, immune cells, and vascular cells.
|
| ln Vivo |
No specific in vivo activity data for 2MeSATP are available in the published literature. As a P2 receptor agonist, it would be expected to modulate purinergic signaling in vivo, affecting neurotransmission, inflammation, and vascular tone, but no animal model studies, pharmacokinetic data, therapeutic efficacy results, or toxicity profiles have been reported. The compound is primarily used as an in vitro research tool.
|
| Enzyme Assay |
Cell-free assays for 2MeSATP typically involve studying its interaction with P2X and P2Y receptors. Standard protocols include radioligand binding assays using membrane preparations from cells expressing P2 receptors with [³⁵S]ATPγS or [³H]-labeled ligands and competing 2MeSATP at concentrations of 0.01-1000 nM. Incubation is performed in assay buffer at 25°C for 60-120 minutes. Bound and free radioligand are separated by filtration and counted by scintillation. Ki values are calculated from competition curves.
|
| Cell Assay |
In vitro cell-based assays for 2MeSATP typically involve cells expressing P2X or P2Y receptors. For P2Y receptors, cells are treated with the compound at concentrations of 0.001-100 μM for 15-30 minutes. Receptor activation is measured by calcium mobilization using fluorescent indicators (e.g., Fluo-4) or by inhibition or stimulation of cAMP accumulation. For P2X receptors, electrophysiological recordings (patch-clamp) are used to measure inward currents. EC50 values are calculated from concentration-response curves. Cytotoxicity is assessed by MTT or LDH assay.
|
| Animal Protocol |
No published in vivo animal experimental protocols are available for 2MeSATP. For related P2 receptor agonists, standard protocols involve administration to rodent models via intravenous, intrathecal, or intraperitoneal routes at doses of 0.01-10 mg/kg, with assessment of effects on pain sensitivity (tail-flick, formalin test), inflammation (carrageenan-induced paw edema), or platelet function. Pharmacokinetic parameters are determined from serial blood samples analyzed by LC-MS/MS.
|
| References |
|
| Molecular Formula |
C11H14N5NA4O13<
|
|---|---|
| Molecular Weight |
641.19992685318
|
| Exact Mass |
640.911
|
| CAS # |
100020-57-3
|
| PubChem CID |
16218831
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
37
|
| Complexity |
825
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CSC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])[O-])O)O)N.[Na+].[Na+].[Na+].[Na+]
|
| InChi Key |
UEEFBRHXFDJPTA-KWIZKVQNSA-J
|
| InChi Code |
InChI=1S/C11H18N5O13P3S.4Na/c1-33-11-14-8(12)5-9(15-11)16(3-13-5)10-7(18)6(17)4(27-10)2-26-31(22,23)29-32(24,25)28-30(19,20)21;;;;/h3-4,6-7,10,17-18H,2H2,1H3,(H,22,23)(H,24,25)(H2,12,14,15)(H2,19,20,21);;;;/q;4*+1/p-4/t4-,6-,7-,10-;;;;/m1..../s1
|
| Chemical Name |
2-(Methylthio)adenosine 5'-triphosphate tetrasodium salt
|
| Synonyms |
2MeSATP 2-MeS-ATP tetrasodium salt 2-MeS ATP 4Na salt2-MeS-ATP tetrasodium salt2 MeS ATP tetrasodium salt
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ~50 mg/mL (~78.0 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5596 mL | 7.7979 mL | 15.5958 mL | |
| 5 mM | 0.3119 mL | 1.5596 mL | 3.1192 mL | |
| 10 mM | 0.1560 mL | 0.7798 mL | 1.5596 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
